X
Edition:
United States

  • Business
    • Business Home
    • Legal
    • Deals
    • Aerospace & Defense
    • Finance
    • Autos
    • Reuters Summits
    • ADventures
    • Data Dive
  • Markets
    • Markets Home
    • U.S. Markets
    • European Markets
    • Asian Markets
    • Global Market Data
    • Indices
    • Stocks
    • Bonds
    • Currencies
    • Commodities
    • Futures
    • Funds
    • Earnings
    • Dividends
  • World
    • World Home
    • U.S.
    • Special Reports
    • Reuters Investigates
    • Euro Zone
    • Middle East
    • China
    • Japan
    • Mexico
    • Brazil
    • Africa
    • Russia
    • India
  • Politics
    • Politics Home
    • Polling Explorer
    • Live: Trump's First 100 Days
    • What Voters Want
    • Supreme Court
  • Tech
    • Technology Home
    • Science
    • Top 100 Global Innovators
    • Media
    • Environment
    • Innovation
  • Commentary
    • Commentary Home
    • Podcasts
  • Breakingviews
    • Breakingviews Home
    • Breakingviews Video
  • Money
    • Money Home
    • Retirement
    • Lipper Awards
    • Analyst Research
    • Stock Screener
    • Fund Screener
  • Life
    • Health
    • Sports
    • Arts
    • Entertainment
    • Oddly Enough
  • Pictures
    • Pictures Home
    • The Wider Image
    • Photographers
    • Focus 360
  • Video
Ex-Insys employees plead not guilty in U.S. drug-kickback case
  • Africa
    América Latina
  • عربي
    Argentina
  • Brasil
    Canada
  • 中国
    Deutschland
  • España
    France
  • India
    Italia
  • 日本
    México
  • РОССИЯ
    United Kingdom
  • United States
Business News | Wed Aug 17, 2016 | 6:05pm EDT

Ex-Insys employees plead not guilty in U.S. drug-kickback case

Jonathan Roper (2nd L), a former Insys Therapeutics Inc district sales manager, and Fernando Serrano (C), a former sales representative at the company walk with Serrano’s lawyer, Jude Cardenas (R), out of federal court after they pleaded not guilty to engaged in a scheme to pay doctors kickbacks to prescribe a fentanyl-based drug the company sells, in Manhattan, New York, U.S., August 17, 2016. Others not identified. REUTERS/Nate Raymond
Jonathan Roper (2nd L), a former Insys Therapeutics Inc district sales manager, and Fernando Serrano (C), a former sales representative at the company walk with Serrano’s lawyer, Jude Cardenas (R), out of federal court after they pleaded not guilty to engaged in a scheme to... REUTERS/Nate Raymond
By Nate Raymond | NEW YORK

NEW YORK Two former Insys Therapeutics Inc employees pleaded not guilty on Wednesday to charges that they engaged in a scheme to pay doctors kickbacks including speaker fees to prescribe a drug containing the opioid fentanyl.

Jonathan Roper, a former Insys district sales manager, and Fernando Serrano, a former sales representative, entered their pleas in Manhattan federal court to charges including that they violated the federal Anti-Kickback Statute.

Their pleas followed their arrests in June and came amid various probes involving Insys and its fentanyl-based sublingual spray Subsys as U.S. law enforcement seek to combat a national opioid abuse epidemic.

Insys, based in Arizona, is not identified by name in the indictment against Roper, of Commack, New York, and Serrano, of Manalapan, New Jersey.

But details in the charging papers about the company and drug match Insys and Subsys. A LinkedIn profile for Serrano shows he previously worked for Insys.

Insys did not respond to requests for comment.

Subsys, which Insys launched in 2012, is a spray approved for managing pain in cancer patients that contains fentanyl, a highly-addictive and regulated synthetic opioid. It generated $329.5 million in net revenue in 2015.

Prosecutors said that to market the spray, Insys established a program in which it paid doctors to act as speakers at educational presentations targeting healthcare professionals.

But prosecutors said many of the programs Roper and Serrano organized were social gatherings at high-end Manhattan restaurants where no education about the spray took place and where audience sign-in sheets contained forged signatures.

Both men were involved in organizing speaker programs for two Manhattan doctors who in 2014 were among the largest prescribers of the spray while earning $147,000 and $112,000 each in speaker fees, the indictment said.

The indictment said Roper and Serrano also were involved in paying for undisclosed alcoholic drinks and meals for doctors.

In court, Assistant U.S. Attorney Noah Solowiejczyk said more charges could be brought.

"The government is continuing to investigate," he said.

Insys has said that it has received information requests or subpoenas from eight other U.S. Attorneys' offices outside of Manhattan regarding doctors it had interacted with.

Those charged include a Connecticut nurse practitioner who in 2015 pleaded guilty to violating the kickback law, and an ex-Insys sales representative in Alabama who pleaded guilty in February to conspiring to violate the statute.

Insys also faces other state and federal investigations related to Subsys including into its sales and marketing practices.

The case is U.S. v. Roper et al, U.S. District Court, Southern District of New York, No. 16-cr-00542.

(Reporting by Nate Raymond in New York; Editing by David Gregorio)

Next In Business News

'Significant uncertainty' about fiscal policy under Trump: Fed's Fischer

COVENTRY, England U.S. Federal Reserve Vice Chair Stanley Fischer said there was significant uncertainty about U.S. fiscal policy under the Trump administration, but the Fed would be strict in meeting targets of creating full employment and getting inflation to 2 percent.

Defections by Sears, Kmart cap week of controversy for Trump brands

Trump-branded consumer products have suffered new blows, with U.S. retailers Sears Holdings Corp and Kmart Corp discontinuing online sales of 31 Trump Home items, while new details emerged showing sales of Ivanka Trump's brand fell in the weeks before Nordstrom Inc stopped carrying her products.

Greece says bailout deal close, Juncker says it's on shaky ground

ATHENS/BERLIN Greek Prime Minister Alexis Tsipras warned international lenders on Saturday not to heap new burdens on his country but said he believed the drawn-out bailout review with them would end well.

MORE FROM REUTERS

Sponsored Content

From Around the WebPromoted by Revcontent

Trending Stories

    Pictures

    Photos of the week

    Sponsored Topics

    X
    Follow Reuters:
    • Follow Us On Twitter
    • Follow Us On Facebook
    • Follow Us On RSS
    • Follow Us On Instagram
    • Follow Us On YouTube
    • Follow Us On LinkedIn
    Subscribe: Feeds | Newsletters | Podcasts | Apps
    Reuters News Agency | Brand Attribution Guidelines | Careers

    Reuters is the news and media division of Thomson Reuters. Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Learn more about Thomson Reuters products:

    Eikon
    Information, analytics and exclusive news on financial markets - delivered in an intuitive desktop and mobile interface
    Elektron
    Everything you need to empower your workflow and enhance your enterprise data management
    World-Check
    Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks
    Westlaw
    Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology
    ONESOURCE
    The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs
    CHECKPOINT
    The industry leader for online information for tax, accounting and finance professionals

    All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.

    • Site Feedback
    • Corrections
    • Advertising Guidelines
    • Cookies
    • Terms of Use
    • Privacy Policy